Abstract

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Steven M Horwitz ...
Blood | VOL. 136
Steven M Horwitz, et. al.Steven M Horwitz ...
05 Nov 2020
Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
Youn H Kim ...
Blood | VOL. 134
Youn H Kim, et. al.Youn H Kim ...
13 Nov 2019
The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
Steven M Horwitz ...
Blood | VOL. 132
Steven M Horwitz, et. al.Steven M Horwitz ...
29 Nov 2018
Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group
Gian Matteo Rigolin ...
Blood | VOL. 136
Gian Matteo Rigolin, et. al.Gian Matteo Rigolin ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors.
Nayoung Kwon ... Diane S Krause
Blood | VOL. -
Nayoung Kwon, et. al.Nayoung Kwon ... Diane S Krause
05 Aug 2024
Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study.
David T Yeung ... Timothy P Hughes
Blood | VOL. -
David T Yeung, et. al.David T Yeung ... Timothy P Hughes
05 Aug 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Esteban Arrieta-Bolaños ... Katharina Fleischhauer
Blood | VOL. -
Esteban Arrieta-Bolaños, et. al.Esteban Arrieta-Bolaños ... Katharina Fleischhauer
05 Aug 2024
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression
Belén Lopez-Millan ... Clara Bueno
Blood | VOL. -
Belén Lopez-Millan, et. al.Belén Lopez-Millan ... Clara Bueno
02 Aug 2024
View more papers